This publication has been discontinued on July 19, 2011.
Aging US population, increasing number of cancer incidences to drive double-digit growth through 2009
The overall US market for cancer therapies and treatments is projected to increase ten percent per year through 2009 to $27.1 billion, which compares favorably to the outlook for both gross domestic product and national health expenditures in the aggregate. The principal factor driving growth will be an increase in the number of cancer incidences as the population ages, since most cancers strike individuals aged 55 and over.
Advanced therapies to fortify overall growth
Projected growth in total cancer therapy demand masks sharp differences in prospects for the constituent components making up the market. In this case, a less sanguine outlook is forecast for traditional treatments such as cancer surgery and chemotherapy, and strong prospects exist for advanced therapies based on cancer vaccines, biotechnology, nanotechnology and stem cells (although the latter two are expected to emerge over a longer term outlook). The prognosis for hormonal therapies is less favorable, due in large measure to a number of proprietary drugs coming off patent.
Biotechnology cancer therapies are already beginning to proliferate in a major way, with drugs achieving FDA approval for treating metastatic colon cancer and metastatic non-small cell lung cancer, with numerous others nearing approval and in various clinical and pre-clinical trial stages. Biotechnology cancer therapies offer highly precise treatment targeting the cancer cells themselves (while not affecting
healthy cells), utilizing genetic materials, proteins and monoclonal antibodies.
Trend towards outpatient treatment to continue
Maintaining established trends, an increasing number of cancer treatments will be administered in outpatient facilities as opposed to in-patient (hospital) settings, due to greater patient comfort and convenience, and cost considerations. In addition, an increasing number of therapies (especially with respect to conventional treatments such as chemotherapy) will be made in oral formulations, allowing for growth in the home health care market as well.
As biotechnology drugs continue to command a higher share of the overall cancer therapy market, traditional pharmaceutical companies will seek to participate by investing in and acquiring biotech concerns, a trend that is already beginning to take shape in the health care sector.
Study coverage
Specific information about therapies and treatments available to cancer patients of various types, as well as the markets providing such care is examined in a new Freedonia study, Cancer Therapies, which historical data plus forecasts to 2009 and 2014 are presented by type of cancer and by type of provider.
The study also examines advances in cancer therapy technology, including both available and emerging biotechnology treatments, and those with longer term potential, such as nanotechnology and stem cells. Socioeconomic and demographic factors are also discussed, such as the health care financing environment, aging of the population and incidence cancer and other diseases. In addition, an overview of the industry structure analyzes the key variables driving competition in this integral segment of the health care industry, and includes profiles for 26 US industry participants.
TABLE OF CONTENTS
INTRODUCTION
I. EXECUTIVE SUMMARY
II. MARKET ENVIRONMENT
- General
- Economic Environment
- Cyclical Trends
- Long-Term Trends
- Demographic Patterns
- Health Care Environment
- Health Insurance & Reimbursement
- Medical Conditions
- Acute Conditions
- Chronic Conditions
- Cancer Incidence & Indicators
- National Health Expenditures
- Medical Providers
- Pharmaceuticals Industry Overview
- Biotechnology Industry Overview
- Cost/Pricing Dynamics
- Regulatory Environment
- Multinational Dynamics
- World Cancer Therapies Market
- Trends in US Foreign Trade
III. TECHNOLOGY
- General
- Traditional Cancer Treatments
- Surgery
- Radiation
- Chemotherapy
- Advanced Cancer Therapies
- Biotechnology-Based
- Cancer Vaccines
- Nanotechnology-Based
- Stem Cells
- Chemotherapy Adjuvants
- Therapy Delivery Systems
- Other Technological Issues
- Cancer Screening & Imaging Systems
- Health Care Information Systems
IV. PRODUCTS & SERVICES
- General
- Therapies by Type of Cancer
- Breast
- Digestive System
- Genital System
- Leukemia
- Lymphoma
- Respiratory System
- Skin
- Urinary System
- Other
- Therapies by Product/Procedure
- Chemotherapy Drugs
- Mitotic Inhibitors
- Antimetabolites
- Alkylating Agents
- Other Types
- Surgery
- Radiation Therapy
- Biotechnology-Based Drugs
- Other/Advanced
- Hormonal Therapy
- Vaccines
- Nanotechnology
- Stem Cells & Other
- General
- Hospitals
- Market Overview
- Cancer Therapies Outlook
- Outpatient Facilities
- Market Overview
- Cancer Therapies Outlook
- Physicians Offices
- Market Overview
- Cancer Therapies Outlook
- Other Markets
- Home Health Care
- Educational & Research Institutions
VI. INDUSTRY STRUCTURE
- General
- Industry Composition & Market Share
- Research & Product Development
- Manufacturing
- Marketing & Distribution
- Financial Issues & Requirements
- Mergers, Acquisitions & Industry Restructuring
- Strategic Partnerships
COMPANY PROFILES
- Albany Molecular Research Incorporated
- American Pharmaceutical Partners Incorporated
- Amgen Incorporated
- AstraZeneca plc
- Aton Pharma Incorporated, see Merck & Company
- Incorporated
- Aventis Pharmaceuticals Incorporated, see Sanofi-Aventis
- Biogen Idec Incorporated
- Bristol-Myers Squibb Company
- Cell Pathways Incorporated, see OSI Pharmaceuticals
- Incorporated
- Cell Therapeutics Incorporated
- Cephalon Incorporated
- CIMA LABS Incorporated, see Cephalon Incorporated
- Corixa Corporation, see GlaxoSmithKline plc
- Genentech Incorporated
- Genzyme Corporation
- GlaxoSmithKline plc
- Hoffmann-La Roche Incorporated, see Roche Holding
- Limited
- ILEX Oncology Incorporated, see Genzyme Corporation
- ImClone Systems Incorporated
- Johnson & Johnson
- Kirin-Amgen Incorporated, see Amgen Incorporated
- Ligand Pharmaceuticals Incorporated
- Lilly (Eli) and Company
- Merck & Company Incorporated
- MGI Pharma Incorporated
- Millennium Pharmaceuticals Incorporated
- Novartis International AG
- Ortho Biotech Products LP, see Johnson & Johnson
- OSI Pharmaceuticals Incorporated
- Pfizer Incorporated
- Pharmion Corporation
- Radiation Therapy Services Incorporated
- Roche Holding Limited
- Salmedix Incorporated, see Cephalon Incorporated
- Sanofi-Aventis
- Sanofi-Synthelabo Incorporated, see Sanofi-Aventis
- Schering-Plough Corporation
- Therakos Incorporated, see Johnson & Johnson
- Tibotec Therapeutics, see Johnson & Johnson
- Tularik Incorporated, see Amgen Incorporated
- 21st Century Oncology Incorporated, see Radiation Therapy
- Services Incorporated
- US Oncology Incorporated
- Wyeth
- Zycos Incorporated, see MGI Pharma Incorporated
- Other Companies Mentioned in Study
LIST OF TABLES
SECTION I -- EXECUTIVE SUMMARY
- Summary Table
SECTION II -- MARKET ENVIRONMENT
- 1 Macroeconomic Environment
- 2 Cancer Therapies Market Trends, 1994-2004
- 3 Resident Population by Age & Sex
- 4 Health Care Indicators
- 5 Medical Conditions
- 6 Cancer Incidences & Deaths
- 7 National Health Expenditures
- 8 Medical Providers
- 9 Pharmaceuticals & Biotechnology Market Indicators
- 10 World Cancer Therapies Market
- 11 US Foreign Trade in Cancer Therapy Drugs
SECTION IV -- PRODUCTS & SERVICES
- 1 Cancer Therapies Demand
- 2 Therapies Demand by Type of Cancer
- 3 Breast Cancer Therapies Demand
- 4 Digestive System Cancer Therapies Demand
- 5 Genital System Cancer Therapies Demand
- 6 Leukemia Therapies Demand
- 7 Lymphoma Therapies Demand
- 8 Respiratory System Cancer Therapies Demand
- 9 Skin Cancer Therapies Demand
- 10 Urinary System Cancer Therapies Demand
- 11 Other Cancers Therapies Demand
- 12 Therapies Demand by Product/Procedure
- 13 Chemotherapy Drugs Demand
- 14 Cancer Surgery Demand
- 15 Cancer Radiation Therapy Demand
- 16 Biotechnology-Based Cancer Drugs Demand
- 17 Other/Advanced Cancer Therapies Demand
SECTION V -- MARKETS
- 1 Cancer Therapies Market by Institution/Provider
- 2 Hospital Indicators
- 3 Hospital Cancer Therapies Market
- 4 Outpatient Facilities Indicators
- 5 Outpatient Facilities Cancer Therapies Market
- 6 Physicians Indicators
- 7 Physicians Offices Cancer Therapies Market
- 8 Other Cancer Therapies Markets
SECTION VI -- INDUSTRY STRUCTURE
- 1 Research & Development Spending Patterns: Selected
- Cancer Therapy Companies
- 2 Capital Spending Patterns: Selected Cancer Therapy
- Companies
- 3 Composite Financial Ratios: Selected Cancer Therapy
- Companies, 2004
- 4 Selected Acquisitions & Divestitures
- 5 Selected Strategic Partnerships
- 6 Revenue & Profits Data: Selected Cancer Therapy
- Companies, 2004
LIST OF CHARTS
SECTION II -- MARKET ENVIRONMENT
- 1 Cancer Therapies Market Volatility
- 2 New Cancer Incidences by Type, 2004
- 3 Cancer Therapies Pricing Patterns, 1994-2014
SECTION IV -- PRODUCTS & SERVICES
- 1 Cancer Therapies Demand by Type of Cancer, 2004
- 2 Cancer Therapies Demand by Product/Procedure, 2004
SECTION V -- MARKETS
- 1 Cancer Therapies Market by Institution/Provider, 2004
SECTION VI -- INDUSTRY STRUCTURE
- 1 US Cancer Therapies Market Share by Company, 2004
